Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4961400 | 0.84 | GPR3 (0.54) | GPR3MCL1 | |
| SCHEMBL4160573 | 0.72 | GPR3 (0.39) | GPR3MAPK1MCL1CA12CA9 | |
| SCHEMBL13864490 | 0.71 | ALDH1A1 (0.50) | GPR3MAPK1MCL1CA12CA9 | |
| SCHEMBL1293964 | 0.69 | ALDH1A1 (0.56) | GPR3MAPK1MCL1CA12CA9 | |
| SCHEMBL30729663 | 0.69 | ALDH1A1 (0.56) | GPR3MAPK1MCL1CA12CA9 | |
| SCHEMBL9171706 | 0.67 | ALDH1A1 (0.53) | MAPK1MCL1 | |
| SCHEMBL4160530 | 0.67 | ALDH1A1 (0.43) | GPR3CA9 | |
| SCHEMBL9927301 | 0.67 | GPR3 (0.39) | GPR3MAPK1MCL1CA12CA9 | |
| SCHEMBL21234346 | 0.67 | GPR3 (0.39) | GPR3MAPK1MCL1CA12CA9 | |
| SCHEMBL3875482 | 0.67 | ALDH1A1 (0.41) | GPR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069408-A1 | TRICYCLIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069408-A1 | TRICYCLIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS | TFRC, SLC40A1, FECH | GPR3 1404/4885MAPK1 4346/4885MCL1 1367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.